AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has made a 21.48% comeback from a 12-month low price of $0.49. It was seen 3.62% higher, changing the price to $0.6, when the closing bell rang on 3/14/2019. At a recent session, the prices were hovering between $0.5674 and $0.61. This company shares are 191.67% off its target price of $1.75 and the current market capitalization stands at $74.18M. The recent change has given its price a -47.59% deficit over SMA 50 and -83.4% deficit over its 52-week high. The stock witnessed -0.67% declines, -70.64% declines and -79.31% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AVEO’s volatility during a week at 5.76% and during a month it has been found around 8.11%.AVEO Pharmaceuticals, Inc. (AVEO) Top Holders
Institutional investors currently hold around $29 million or 41.9% in AVEO stock. Look at its top three institutional owners: Nea Management Company, Llc owns $12.02 million in AVEO Pharmaceuticals, Inc., which represents roughly 16.2% of the company’s market cap and approximately 41.43% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 7,357,716 shares of the stock are valued at $4.23 million. The third largest holder is Vanguard Group Inc, which currently holds $3.01 million worth of this stock and that ownership represents nearly 4.06% of its market capitalization.AVEO Pharmaceuticals, Inc. 13F Filings
At the end of December reporting period, 52 institutional holders increased their position in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) by some 7,651,072 shares, 45 decreased positions by 7,802,943 and 24 held positions by 34,872,417. That puts total institutional holdings at 50,326,432 shares, according to SEC filings. The stock grabbed 22 new institutional investments totaling 1,548,772 shares while 21 institutional investors sold out their entire positions totaling 6,064,275 shares.AVEO Pharmaceuticals, Inc. (AVEO) Analyst Guide
Several analysts have released their opinion on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), with 1 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.25 average brokerage recommendation [T1].